Hart R G, Boop B S, Anderson D C
Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio 78284-7883, USA.
Stroke. 1995 Aug;26(8):1471-7. doi: 10.1161/01.str.26.8.1471.
Intracranial hemorrhage is the most feared and lethal complication of oral anticoagulation. We review the frequency, predictors, and prognosis of this most common neurological complication of oral anticoagulation.
Anticoagulation to conventional intensities increases the risk of intracranial hemorrhage 7- to 10-fold, to an absolute rate of nearly 1%/y for many stroke-prone patients. Most (70%) anticoagulant-related intracranial hemorrhages are intracerebral hematomas (approximately 60% are fatal); the bulk of the remainder are subdural hematomas. Predictors of anticoagulant-related intracerebral hematoma are advanced patient age, prior ischemic stroke, hypertension, and intensity of anticoagulation. In approximately half of anticoagulated patients with intracerebral hematoma the bleeding evolves slowly over 12 to 24 hours, and emergency reversal of anticoagulation is crucial.
Both patient factors and anticoagulation intensity importantly influence the rate of anticoagulation-related intracranial hemorrhage. Patient-related risk factors for this complication overlap with those for ischemic stroke. The risk/benefit equation of anticoagulation for elderly, stroke-prone patients is complex and differs from that for younger patients. The absolute rate reduction (not the relative risk reduction) of ischemic stroke by anticoagulation is the critical issue and must offset accentuation of often lethal brain hemorrhage.
颅内出血是口服抗凝治疗最可怕且致命的并发症。我们回顾了这种口服抗凝治疗最常见的神经并发症的发生率、预测因素及预后情况。
抗凝至常规强度会使颅内出血风险增加7至10倍,对于许多易患中风的患者,绝对发生率接近每年1%。大多数(70%)与抗凝相关的颅内出血为脑内血肿(约60%是致命的);其余大部分是硬膜下血肿。与抗凝相关的脑内血肿的预测因素包括患者高龄、既往缺血性中风、高血压及抗凝强度。在约一半患有脑内血肿的抗凝患者中,出血会在12至24小时内缓慢进展,紧急逆转抗凝至关重要。
患者因素及抗凝强度均会显著影响与抗凝相关的颅内出血发生率。该并发症的患者相关风险因素与缺血性中风的风险因素重叠。对于老年、易患中风的患者,抗凝治疗的风险/获益权衡很复杂,与年轻患者不同。抗凝治疗使缺血性中风的绝对发生率降低(而非相对风险降低)是关键问题,且必须抵消常致命的脑出血风险增加。